The Reproductive Endocrinology Clinic at the USZ has been involved for many years in the research and treatment of endometriosis, a complex, chronic disease that affects around one in ten women and is often associated with severe pain and fertility problems. Despite their widespread use, there is still a great need for causally effective therapies.
To close this gap, the spin-off FimmCyte AG was founded in 2022 as a result of research at the University Hospital Zurich and the University of Zurich. This represents an important step towards a new type of causal treatment.
The focus is on an innovative immunological therapy that aims to correct the dysregulation of the immune system – a central cause of inflammation and adhesions in endometriosis. The aim is not only to alleviate pain, but also to slow down the progression of the disease in the long term. In the long term, this could make a therapy available for the first time that directly addresses the disease mechanisms and enables patients to achieve a lasting improvement in their quality of life.
An important next step is now a strategic research collaboration with the international pharmaceutical company Gedeon Richtera leading provider in the field of women’s health. The aim of the collaboration is to further advance the development of the therapy developed by FimmCyte and to accelerate the path to clinical application.
“We are very pleased about this cooperation, as it will enable us to advance the development of the innovative immunological therapy we have developed for endometriosis for use in the clinic so that it will be available as soon as possible for widespread use instead of and in addition to the treatment options currently available,” says Prof. Brigitte Leeners, Clinic Director.
FimmCyte was founded in 2022 as a spin-off of the University of Zurich and the University Hospital Zurich. The company develops targeted immunotherapies for chronic fibroinflammatory diseases and is supported by the USZ Health Innovation Hub, Innosuisse, the UZH Life Sciences Fund and BaseLaunch.
More information about FimmCyte